The first European patients in the Phase 3 'Proof-HD' trial with Pridopidine in Huntington's disease are from Italy and Germany

Proof-HD' trial with Pridopidine in Huntington's disease


The first two Italian patients started the trial today, January 20, 2021, in Rome, at the CSS-Mendel Institute, section of IRCCS Casa Sollievo della Sofferenza and Coordinating Center for Italy, under the guidance of Principal Investigator Prof. Ferdinando Squitieri.

Healthe-RND: Toward a telemedicine model for Huntington's and rare neurodegenerative diseases

Healthe-RND: verso un modello di telemedicina specifico per Huntington e malattie rare neurodegenerative


COVID-19 quickly disrupted customary clinical practices. Within few weeks, as quarantine and social distancing became the norm, in-person medical appointments became increasingly sporadic and were replaced by those conducted with audiovisual tools. In doing so, telemedicine, hitherto on the margins, became protagonist.

PTC Therapeutics has started in-human Huntington’s disease trial with PTC518

PTC Therapeutics: avviata la sperimentazione della molecola PTC518 per il trattamento della malattia di Huntington


In an official statement of 17 November 2020, PTC Therapeutics announced the initiation of a Phase 1 clinical trial to evaluate PTC518 in healthy volunteers. The Phase 1 study includes both single and multiple ascending dosing regimens that will help establish the safety, pharmacology, and dose selection for the Phase 2 study.

The emotions' recognition and the adequacy of visual scanning in a recent study on pre-manifest HD

Malattia di Huntington: uno studio individua la relazione tra il riconoscimento delle emozioni e l’adeguatezza della scansione visiva


A recent study published in “Experimental Brain Research”, a journal of the Nature Group, investigates the relationship between the ability to visually scan and the difficulty of recognizing others’ emotions, in the pre-symptomatic phase of Huntington's disease (preHD). Why is this important?

Huntington’s Disease: Prilenia Enrolls First Patients into PROOF-HD Clinical Trial

Huntington’s Disease: Prilenia Enrolls First Patients into its PROOF-HD Trial


On October 28th, in an official press release, Prilenia Therapeutics , a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, announced the enrollment of the first patients in the U.S. into PROOF-HD, a global phase 3 clinical trial for Huntington’s Disease (HD)